Type | Sym | Class | Transaction | Value $ | Shares | Change % | Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | EXC | Common Stock | +Options Exercise | +109,928 | +37.36% | 404,180 | Feb 8, 2022 | Direct | F1 | ||
transaction | EXC | Common Stock | -Tax liability | -$2,793,290 | -48,723 | -12.05% | $57.33 | 355,457 | Feb 8, 2022 | Direct | |
transaction | EXC | Common Stock | -Disposed to Issuer | -$3,508,883 | -61,205 | -17.22% | $57.33 | 294,252 | Feb 8, 2022 | Direct | |
holding | EXC | Common Stock | 28,500 | Feb 8, 2022 | Held by trust for benefit of son | ||||||
holding | EXC | Common Stock | 28,500 | Feb 8, 2022 | Held by trust for benefit of daughter |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | EXC | Performance Shares 2019-2021 | +Grant/Award | +109,928 | 109,928 | Feb 8, 2022 | Common Stock | 109,928 | $0.00 | Direct | F2, F3 | |||
transaction | EXC | Performance Shares 2019-2021 | -Options Exercise | -109,928 | -100% | 0 | Feb 8, 2022 | Common Stock | 109,928 | $0.00 | Direct | F2 |
Id | Content |
---|---|
F1 | Common shares acquired through conversion of previously granted and vested performance share award under the Exelon Long Term Incentive Plan. |
F2 | Performance share award granted pursuant to the Exelon Long Term Incentive Plan for the three-year performance period referenced in Column 1 based on the Compensation Committee's determination of performance achieved for the period. Each performance share represents the right to receive one share and/or cash pursuant to the Plan's terms with respect to individual stock ownership levels. Performance share awards vest immediately upon their grant date. |
F3 | Performance criteria was approved by the Exelon Compensation Committee; however Mr. Crane's award amount was further subject to Exelon board approval. |